The menopause treatment fezolinetant has been predicted as a “gamechanger” by experts for thousands of women who suffer from hot flushes. The drug, which is the first non-hormonal menopause treatment, ...

Please provide your email address to receive an email when new articles are posted on . All three phase 3 SKYLIGHT studies showed fezolinetant to be an acceptable treatment option for postmenopausal ...

PHILADELPHIA -- Fezolinetant (Veozah) improved menopause-related vasomotor symptoms in women unsuited or unwilling to take hormone therapy, according to a pooled analysis of two phase III studies. The ...

Please provide your email address to receive an email when new articles are posted on . Fezolinetant reduced vasomotor symptom frequency more than paroxetine, desvenlafaxine and gabapentin ER.

Extensive and growing evidence continues to reinforce fezolinetant as an effective treatment for moderate to severe VMS associated with menopause Preliminary analysis from OPTION-VMS observational ...

MINNEAPOLIS — Women taking fezolinetant for menopausal vasomotor symptoms did not experience any significant change in weight or body mass index (BMI) after a year of taking the medication, according ...

Astellas Pharma Inc. presents 24-week results from the phase 3b DAYLIGHT clinical trial examining the efficacy and safety of fezolinetant, an investigational oral, nonhormonal compound being studied ...

The presentations, which feature three Late Breaking Abstracts (LBA), will include two preliminary analyses from the OPTION-VMS study. These analyses evaluate, in a real-world setting, both the ...

Add Yahoo as a preferred source to see more of our stories on Google. (iStock) The menopause treatment fezolinetant has been predicted as a “gamechanger” by experts for thousands of women who suffer ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...